Key facts
- It has raised $3.5M; the latest was Seed Round ($3.5M) in Nov 2025.
- Notable investors include Turenne Groupe, Armand Bensussan, Gilles Alberici, Octalfa.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ventuno Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Ventuno Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ventuno Biotech
Developer of immunotherapies intended for cancer treatment. The company offers scientific research and technologies to develop therapeutic strategies that harness the body's immune system to specifically target and eliminate cancer cells in difficult-to-treat tumors, enabling the oncology market to access new, life-changing therapeutic options for patients.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2025
- Employees
- 4
- Website
- ventuno-biotech.com/
- Ownership
- Privately Held (backing)
Ventuno Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ventuno Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ventuno Biotech in its N-PORT filings yet. We sweep new filings monthly.